A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 20 May 2025
At a glance
- Drugs Gemcitabine (Primary) ; Glofitamab (Primary) ; Oxaliplatin (Primary) ; Obinutuzumab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Roche
Most Recent Events
- 20 Feb 2025 Planned primary completion date changed from 31 Mar 2027 to 31 Jan 2027.
- 11 Feb 2025 New trial record